Composition for delaying ovarian aging and improving polycystic ovary syndrome and preparation method thereof
By combining flaxseed lignol, D-chinositol, red ginseng and zinc-containing compounds, the shortcomings of ovarian aging and polycystic ovarian syndrome treatment in the prior art are solved, and safe and effective delay is achieved Effects of ovarian aging and improving symptoms.
Patent Information
- Application Number
- CN202211018088.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-24
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective drugs to treat ovarian aging and improve polycystic ovarian syndrome. Hormone replacement therapy poses safety risks, and commercially available food ingredients are simple and the treatment effect is not ideal.
Provide a composition, including flaxseed lignol, D-chinositol, red ginseng and zinc-containing compounds, to overcome the instability of flaxseed lignol in aqueous solution of pH 2 to pH 6, and synergistically increase the effect. Improves symptoms of ovarian aging and polycystic ovarian syndrome.
Significantly improve polycystic ovarian syndrome and menopausal syndrome, delay ovarian aging, and long-term use is safe and has no side effects.
Smart Images

Figure BDA0003813118450000071 
Figure BDA0003813118450000072 
Figure BDA0003813118450000081
Abstract
Description
Technical Field
[0001] The invention relates to the fields of medicine and food, and in particular to a composition for delaying ovarian aging and improving polycystic ovary syndrome and a preparation method thereof. Background Art
[0002] The main function of the ovaries is to ovulate and secrete female hormones. With the increase of age, women's ovarian function begins to decline around the age of 45-50, estrogen levels decrease, and they enter the perimenopause. However, some women before the age of 40 suffer from premature ovarian failure due to environmental, dietary, unhealthy living habits, psychological or pathological factors. In addition, long-term menstrual irregularities and polycystic ovary syndrome lead to infrequent menstruation, amenorrhea or hormonal abnormalities in women of childbearing age, which is also an important factor in accelerating ovarian aging. Ovarian aging can cause physical and physiological changes in women, such as menstrual changes, osteoporosis, increased blood pressure, increased skin wrinkles, or symptoms of menopause such as hot flashes, mood stability and irritability, and a decline in the body's immune system, which in turn accelerates aging and seriously affects women's quality of life.
[0003] At present, there is no clear and effective drug for the treatment of ovarian aging. The main method is hormone replacement therapy (HRT). Although HRT therapy can eliminate menopausal symptoms to a certain extent and reduce the risk of osteoporosis, there is a phenomenon of recurrence after stopping hormone therapy, and it increases the risk of breast cancer, endometrial cancer, thrombosis, and stroke. Therefore, HRT therapy is not a safe and effective treatment method and is not the best choice for perimenopausal women. In addition, there is traditional Chinese medicine treatment, taking decoctions or granules. The treatment cycle of traditional Chinese medicine is relatively long. For working women, it is inconvenient to take medicine and they cannot take medicine on time, making it difficult to adhere to treatment.
[0004] There are relatively few types of food or health food on the market that can improve polycystic ovary syndrome or delay ovarian aging. The main ingredients are soy isoflavones, which have simple ingredients and unsatisfactory therapeutic effects. Summary of the invention
[0005] In view of this, the present invention provides a composition for delaying ovarian aging and improving polycystic ovary syndrome and a preparation method thereof. The components in the composition of the present invention synergize with each other, can significantly improve polycystic ovary syndrome and menopausal syndrome, achieve the effect of delaying ovarian aging, and can be used for a long time, safe and without side effects.
[0006] In order to solve the above technical problems, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a composition for delaying ovarian aging and improving polycystic ovary syndrome, the composition comprising:
[0008] Flaxseed lignans, D-chiro-inositol, red ginseng, and zinc-containing compounds.
[0009] Furthermore, the composition also includes: rose.
[0010] Furthermore, the source of the flaxseed lignans includes flaxseeds; the flaxseeds are concentrated flaxseed powders that have been concentrated, and the content of flaxseed lignans in the concentrated flaxseed powders is ≥5%; and / or
[0011] The source of the D-chiro-inositol includes carob; the carob is an extracted carob extract, and the content of D-chiro-inositol in the carob extract is ≥80%.
[0012] Furthermore, the zinc-containing compound includes at least one of zinc sulfate, zinc citrate, zinc citrate trihydrate, zinc gluconate, zinc oxide, zinc lactate, zinc acetate and zinc chloride.
[0013] Furthermore, in the composition, the mass ratio of flaxseed lignan: D-chiro-inositol: red ginseng: zinc-containing compound is (0.1-15): (0.4-12): (0.7-15): (0.01-0.1); or
[0014] The mass ratio of flaxseed concentrated powder: carob extract: red ginseng: zinc-containing compound is (2-15): (0.5-12): (0.7-15): (0.01-0.1).
[0015] Furthermore, in the composition, the mass ratio of flaxseed lignan: D-chiro-inositol: red ginseng: rose: zinc-containing compound is (0.1-15): (0.4-12): (0.7-15): (2-15): (0.01-0.1).
[0016] Furthermore, the composition further comprises: vitamins; and / or
[0017] Minerals; and / or
[0018] One or more pharmaceutically acceptable excipients.
[0019] In a second aspect, the present invention provides a method for preparing the composition as described above, wherein the preparation method comprises: mixing the flaxseed lignan, D-chiro-inositol, red ginseng and a zinc-containing compound to obtain the composition.
[0020] In a third aspect, the present invention provides use of the composition as described above in the preparation of a drug for delaying ovarian aging and improving polycystic ovary syndrome.
[0021] Furthermore, the dosage form of the drug includes tablets, liquid preparations, capsules and powders.
[0022] The beneficial effects of the above technical solution of the present invention are as follows:
[0023] The present invention provides a composition for delaying ovarian aging and improving polycystic ovary syndrome, the composition comprising: flax seed lignans, D-chiro-inositol, red ginseng and a zinc-containing compound. The present invention overcomes the problem that flax seed lignans are unstable in an aqueous solution of pH 2 to pH 6 by compounding flax seed lignans with D-chiro-inositol, red ginseng and a zinc-containing compound. At the same time, the above components can play a synergistic role, thereby significantly improving various symptoms of polycystic ovary syndrome and menopause, and further achieving the effect of delaying ovarian aging. DETAILED DESCRIPTION
[0024] In order to further understand the present invention, preferred embodiments of the present invention are described below in conjunction with examples. However, it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than for limiting the present invention.
[0025] In a first aspect, the present invention provides a composition for delaying ovarian aging and improving polycystic ovary syndrome, the composition comprising: flaxseed lignans, D-chiro-inositol, red ginseng and a zinc-containing compound.
[0026] In view of the problem that there is currently no clear and effective drug for treating ovarian aging, the present invention provides a composition for delaying ovarian aging and improving polycystic ovary syndrome, wherein the composition mainly includes flaxseed lignans, D-chiro-inositol, red ginseng and zinc-containing compounds as effective ingredients.
[0027] Among them, flaxseed lignans have strong antioxidant and anti-cancer effects. Flaxseed lignans are also a type of phytoestrogen that is very similar to the physiological activity of human estrogen. As a phytoestrogen, flaxseed lignans not only play a role in the metabolism of endogenous hormones, but also affect cell differentiation and proliferation. When young or perimenopausal women are deficient in estrogen, lignans can act on the estrogen receptors of cells, accelerate cell maturation, stimulate the production of estrogen, and accelerate the production of prolactin, reduce the density of low-density lipoprotein in the serum of menopausal women, delay osteoporosis, etc., and relieve a series of symptoms of menopause. The metabolism of flaxseed lignans in the human body is similar to that of hormones, and it is relatively safe. The most abundant component in flaxseed lignans is secoisolariciresinol diglucoside (SDG), and secoisolariciresinol (SECO) is the glycoside form of SDG. Most flaxseed lignans exist in the form of dimers, and there are also a few trimers and tetramers. They are hydrophilic and can be hydrolyzed by biological enzymes or organic acids. Studies have shown that SDG in flaxseed lignans is unstable in aqueous solutions of pH 2 to pH 6, with a degradation rate of 13%-43%, while the pH of conventional beverages is 3-6, which greatly limits its application in oral liquids. Therefore, it is necessary to provide an effective method to overcome the problem of flaxseed lignans being unstable in aqueous solutions of pH 2 to pH 6. The present invention finds that by compounding flaxseed lignans with D-chiro-inositol, red ginseng and zinc-containing compounds, the problem of flaxseed lignans being unstable in aqueous solutions of pH 2 to pH 6 can be effectively overcome.
[0028] In addition to the function of inositol in promoting liver lipid metabolism, D-chiro-inositol (DCI) also has an insulin sensitizing effect. It can lower blood sugar and improve ovulation in patients with polycystic ovary syndrome (PCOS). It can also regulate hormone balance, improve menstrual disorders, and has special physiological functions such as anti-oxidation, anti-aging, and anti-inflammatory.
[0029] Red ginseng is made from fresh ginseng through soaking, washing, sorting, steaming, airing, and drying. It can be processed into powder or extract according to demand. Red ginseng can greatly replenish vital energy, restore pulse and consolidate deficiency, and replenish qi and blood. Studies have shown that ginsenoside Rg1, the main active ingredient in red ginseng, a proven phytoestrogen, exerts estrogen-like activity on human breast cancer cells (MCF-7) without directly acting on estrogen receptors (ERs). Red ginseng can relieve polycystic ovary syndrome and improve a series of symptoms such as menopausal osteoporosis, night sweats, and palpitations.
[0030] Zinc, a mineral, has been shown in studies to be correlated with serum zinc levels in patients with polycystic ovary syndrome (PCOS) and various indicators of PCOS patients. The serum zinc level in PCOS patients is significantly reduced and is further reduced in PCOS patients with insulin resistance. It is significantly correlated with BMI, TG, HDL and TG / HDL, suggesting that zinc deficiency may play an important role in the physiology and pathology of PCOS.
[0031] According to some embodiments of the present invention, the composition further comprises: rose.
[0032] Rose pollen has the functions of regulating qi and blood, soothing the liver and relieving depression, reducing fat and losing weight, moisturizing and beautifying the skin. It is especially effective for women with menstrual pain and irregular menstruation. Rose contains effective compounds such as lycopene, Rubixanthin, Rugosin A, β-sitosterol, stigmasterol, vitamin E, demethoxycapillarin chromone, β-carotene and quercetin, which can play pharmacological roles such as anti-oxidation, anti-tumor, anti-inflammatory, anti-viral, immunomodulatory and liver protection, and also plays health care functions such as lowering blood sugar, lowering fat, anti-aging and improving skin.
[0033] The composition of the present invention contains effective ingredients of flaxseed lignans, D-chiro-inositol, red ginseng and zinc-containing compounds, and preferably may also contain rose. By using the above effective ingredients in combination, the inventors have found that the above components can play a synergistic role, thereby significantly improving various symptoms of polycystic ovary syndrome and menopause, and further achieving the effect of delaying ovarian aging.
[0034] According to some embodiments of the present invention, the source of flaxseed lignans includes flaxseed; the flaxseed is concentrated flaxseed powder that has been concentrated, and the content of flaxseed lignans in the concentrated flaxseed powder is ≥5%; and / or the source of D-chiro-inositol includes carob; the carob is an extracted carob extract, and the content of D-chiro-inositol in the carob extract is ≥80%.
[0035] Flaxseed contains a high content of flaxseed lignans. When flaxseed is added to a composition as a source of flaxseed lignans, the flaxseed is generally extracted and concentrated. The flaxseed lignan content in the concentrated flaxseed powder is ≥5%. Preferably, the flaxseed lignan content in the concentrated flaxseed powder is ≥30%. Carob contains a high content of D-chiro-inositol. When carob is added to a composition as a source of D-chiro-inositol, the carob is generally extracted. The carob is extracted with hot water, treated with an enzyme, and filtered to obtain an off-white powder, which is a carob extract. The content of D-chiro-inositol in the carob extract is ≥80%. Preferably, the content of D-chiro-inositol in the carob extract is ≥90%.
[0036] According to some embodiments of the present invention, the zinc-containing compound includes at least one of zinc sulfate, zinc citrate, zinc citrate trihydrate, zinc gluconate, zinc oxide, zinc lactate, zinc acetate and zinc chloride.
[0037] According to some embodiments of the present invention, in the composition, the mass ratio of flaxseed lignan: D-chiro-inositol: red ginseng: zinc-containing compound is (0.1-15): (0.5-12): (0.7-15): (0.01-0.1); or the mass ratio of flaxseed concentrated powder: carob extract: red ginseng: zinc-containing compound is (2-15): (0.5-12): (0.7-15): (0.01-0.1).
[0038] Preferably, in the composition, the mass ratio of flaxseed lignan: D-chiro-inositol: red ginseng: zinc-containing compound is (1.5-10): (1.8-6): (1-10): (0.02-0.06). Meanwhile, the mass ratio of flaxseed concentrated powder: carob extract: red ginseng: zinc-containing compound is (5-10): (2-6): (1-10): (0.02-0.06).
[0039] According to some embodiments of the present invention, in the composition, the mass ratio of flaxseed lignan: D-chiro-inositol: red ginseng: rose: zinc-containing compound is (0.1-15): (0.5-12): (0.7-15): (2-15): (0.01-0.1).
[0040] Preferably, in the composition, the mass ratio of flaxseed lignan: D-chiro-inositol: red ginseng: rose: zinc-containing compound is (1.5-10): (1.8-6): (1-10): (6-10): (1-10).
[0041] According to some embodiments of the present invention, the composition further comprises: vitamins; and / or minerals; and / or one or more pharmaceutically acceptable excipients.
[0042] Optionally, the vitamins include vitamin C and vitamin B; the minerals include selenium; and the excipients include fillers, lubricants, and the like.
[0043] In a second aspect, the present invention provides a method for preparing the composition as described above, wherein the preparation method comprises: mixing the flaxseed lignan, D-chiro-inositol, red ginseng and a zinc-containing compound to obtain the composition.
[0044] In a third aspect, the present invention provides use of the composition as described above in the preparation of a drug for delaying ovarian aging and improving polycystic ovary syndrome.
[0045] According to some embodiments of the present invention, the dosage form of the drug includes tablets, liquid preparations, capsules and powders.
[0046] The present invention provides a method for preparing a composition for delaying ovarian aging or improving polycystic ovary syndrome. The preparation method comprises the following steps: weighing flaxseed lignans, D-chiro-inositol, red ginseng and a zinc-containing compound according to the mass fraction of the formula and mixing them to obtain the composition.
[0047] Specifically, the flaxseed lignans may be present in the form of flaxseed concentrated powder, the D-chiro-inositol may be present in the form of carob extract, the red ginseng may be present in the form of red ginseng powder or extract, and the zinc may include zinc citrate and / or zinc gluconate.
[0048] The flaxseed concentrated powder, carob extract, red ginseng powder or extract, zinc citrate and / or zinc gluconate are mixed evenly and packaged to obtain a solid composition; preferably, an additional active ingredient, rose powder, can be added to the above components and mixed evenly.
[0049] Furthermore, purified water, fruit and vegetable juice or fruit powder, flavoring agent, preservative, thickener, etc. can be added to the above solid composition for mixing, filtering, packaging, and sterilization to obtain a liquid beverage;
[0050] Furthermore, fruit powder, flavoring agent, thickener, etc. can be added to the above solid composition for mixing, granulation or not, drying or not, and packaging to obtain a solid beverage;
[0051] Furthermore, excipients and lubricants may be added to the above solid composition for mixing, granulation or not, drying or not, and then tableting or filling to obtain tablets or capsules.
[0052] The present invention will be further described below through some specific embodiments.
[0053] The concentrated flax powder and carob extract used in the following examples and comparative examples are commercially available products, wherein the content of flaxseed lignans in the concentrated flax powder is 40±5%, and the content of D-chiro-inositol in the carob extract is ≥95%.
[0054] Example 1
[0055] Preparation method:
[0056] (1) Prepare the components according to the amounts in Table 1;
[0057] (2) adding all the components into purified water, stirring to dissolve, filling, sealing and sterilizing to obtain a liquid beverage of the composition.
[0058] Embodiments 2 to 7
[0059] The preparation method is the same as that of Example 1. The specific formula composition is shown in Table 1. The numbers in Table 1 are the usage percentages of each component, and the usage percentages are parts by weight. " / " indicates that no addition is made, and "balance" indicates that the rest is purified water.
[0060] Table 1 Components of Examples 1 to 7
[0061]
[0062] Comparative Examples 1 to 6
[0063] The preparation method is the same as that of Example 1. The specific formula composition is shown in Table 2. The numbers in Table 2 are the usage amounts of each component, and the usage amounts are weight parts. " / " indicates that no addition is made, and "appropriate amount" indicates that the pH values of Comparative Examples 1 to 6 and Examples 1 to 7 are kept basically the same by adjusting the usage amount of citric acid.
[0064] Table 2 Components of Comparative Examples 1 to 6
[0065]
[0066]
[0067] test
[0068] 1. Flaxseed lignan stability test
[0069] 1.1 Detection method
[0070] Test samples: Comparative Examples 5-6, Experimental Examples 1-7;
[0071] Test conditions: high temperature (40°C);
[0072] Sampling time: 0 days, 7 days, 14 days, 28 days;
[0073] Test indicators: flax seed lignan content, the determination method refers to the enterprise standard, the HPLC method is used for testing, and the content requirement is 90-110%.
[0074] 1.2 Experimental Results
[0075] The statistical results of flaxseed lignan content are shown in Table 3.
[0076] Table 3 Statistical results of flaxseed lignan content in stability test solution
[0077]
[0078] The results in Table 3 show that after being placed under high temperature conditions for 28 days, the content of flax seed lignans in the samples of comparative examples 5-6 of the present invention was significantly reduced after being placed under high temperature conditions for 7 days, and the content was reduced by about 35% after 7 days; after being placed under high temperature conditions for 28 days, the content of flax seed lignans in experimental examples 1-7 of the present invention decreased slightly, but were all higher than 90%, indicating that the stability of flax seed lignans in the composition of the present invention is significantly higher than that in the comparative example.
[0079] 2. Animal experiment on cystic ovary syndrome model PCOS
[0080] In order to verify the effect of the composition of the present invention in improving polycystic ovary syndrome, the following experiment was conducted:
[0081] 2.1 Grouping and model preparation
[0082] 130 female SD rats aged 8-10 weeks, weighing 250-300g, were randomly divided into a normal group of 10 and a PCOS model group of 120. The normal group was fed conventionally, and the rats in the PCOS model group were subcutaneously injected with 60mg / kg / d of DHEA (dehydroepiandrosterone, IL Company, USA) at the back of the neck from the 23rd day of age for 20 consecutive days. All rats began to fast on the 20th day after injection (i.e., rats were 42 days old). After 12 hours of fasting, blood was collected from the retroorbital vein, serum was separated, and the levels of T androgen (T), follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) in the serum were measured by radioimmunoassay. The changes in the estrous cycle were observed by vaginal smear. Those with a complete estrous cycle and elevated serum T in the vaginal smear were PCOS models.
[0083] The PCOS rats with successful modeling were randomly divided into a model blank group, comparative example groups 1-4, and example groups 1-7.
[0084] 2.2 Administration
[0085] The PCOS rats in the comparative examples 1-4 were gavaged with 2.3 g / kg / d of the samples in the comparative examples 1-4, and the PCOS rats in the examples 1-7 were gavaged with 2.3 g / kg / d of the samples in the examples 1-7 for 21 consecutive days. The normal group and the model blank group were gavaged with an equal volume of 0.9% saline, and all animals were fed with normal feed.
[0086] 2.3 Detection
[0087] All rats were gavaged with physiological saline or comparative or example samples the next day, and blood was collected from the eye sockets after fasting for more than 12 hours, and serum was separated. The levels of T androgen (T), follicle stimulating hormone (FSH), and luteinizing hormone (LH) in the serum were measured by radioimmunoassay. All data were expressed as mean ± standard deviation (x ± s), and statistical analysis was performed using SPSS 11.5 statistical software. One-way analysis of variance was used for comparison among multiple groups, and LSD-t test was used for post hoc multiple comparisons. P < 0.05 was considered statistically significant.
[0088] The results are shown in Tables 4 and 5.
[0089] Table 4 Effect of the composition on polycystic ovary syndrome
[0090]
[0091] Table 4
[0092]
[0093]
[0094] Table 5 Statistical analysis results
[0095]
[0096] Table 5
[0097]
[0098] Note: *P<0.05, **P<0.01, #P>0.05
[0099] From the above analysis results, it can be seen that the T, FSH, and LH levels of the comparative example and the embodiment are significantly different from those of the blank model group PCOS rats, and the embodiment is significantly better than the comparative example; compared with the normal group rats, the comparative example and the embodiment are significantly different, and the embodiment is significantly better than the comparative example, and the LH level of the PCOS rats in Example 2 and Example 5 can be restored to a level with no significant difference from that of the normal rats.
[0100] 3. Animal experiment on premature ovarian failure model POF
[0101] In order to verify the effect of the composition of the present invention in delaying premature ovarian failure, the following experiment was performed:
[0102] 3.1 Grouping and Modeling
[0103] Establishment of rat POF model:
[0104] Fifty female SD rats aged 8-10 weeks, weighing 250-300g, were selected. All rats were screened for normal sexual cycles by vaginal exfoliated cell smears and randomly divided into a normal group of 10 and a POF model group of 40. The normal group was given conventional feeding, and the POF model group was given cisplatin injection (Nuoxin Pharmaceutical, 20ml:20mg) 1.5mg / kg / d intraperitoneal injection for 7 consecutive days. After injection, vaginal secretion samples were taken from female SD rats for 5 consecutive days to observe exfoliated cells. The modeling rats were observed to have disordered sexual cycles, yellow fur color, lack of luster, easy to fall off, and irritable, which means that the modeling was successful.
[0105] The POF rats with successful modeling were randomly divided into a model blank group, a comparative example group, and an example group. There were 10 POF rats in each of the model blank group, comparative example 5, example 2, and example 5.
[0106] 3.2 Administration
[0107] The POF rats in Example 2, Example 5 and Comparative Example 5 were gavaged with 2.3 g / kg / d of the corresponding Example or Comparative Example samples for 21 consecutive days. The normal group and the model blank group were gavaged with an equal volume of 0.9% saline, and all animals were fed with normal feed.
[0108] 3.3 Detection
[0109] The next day after all rats were gavaged with physiological saline or comparative examples or examples, blood was collected from the orbits after fasting for more than 12 hours, and serum was separated. The levels of estradiol (E2) and anti-Mullerian hormone (AMH) in serum were measured by radioimmunoassay. All data were expressed as mean ± standard deviation (x ± s), and statistical analysis was performed using SPSS11.5 statistical software. One-way analysis of variance was used for comparison among multiple groups, and LSD-t test was used for post hoc multiple comparisons. P < 0.05 was considered statistically significant.
[0110] The results are shown in Table 6.
[0111] Table 6 Effect of the composition on rats with premature ovarian failure
[0112]
[0113] Note: *P<0.05, **P<0.01
[0114] From the above analysis results, it can be seen that for POF model rats, there are significant differences in E2 and AMH levels between the blank group and the normal group, and there are significant differences between Comparative Example 5, Example 2 and Example 5 and the blank model group, and the E2 and AMH levels of the example rats are significantly lower than those of the comparison example 5 rats, among which the results of Example 5 are the best.
[0115] The above test results show that the composition of the present invention has excellent effects of improving the stability of flaxseed wood powder, delaying ovarian aging and improving polycystic ovary symptoms.
[0116] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A composition for delaying ovarian aging and improving polycystic ovary syndrome, characterized in that: The active ingredients of the composition are: flaxseed lignans, D-chiro-inositol, red ginseng, zinc compounds, and rose; In the composition, the mass ratio of flaxseed lignan: D-chiro-inositol: red ginseng: rose: zinc-containing compound is (0.1-15): (0.4-12): (0.7-15): (2-15): (0.01-0.1).
2. The composition according to claim 1, characterized in that The source of the flaxseed lignans includes flaxseed; the flaxseed is concentrated flaxseed powder that has been concentrated, and the content of flaxseed lignans in the concentrated flaxseed powder is ≥5%; and / or The source of the D-chiro-inositol includes carob; the carob is an extracted carob extract, and the content of D-chiro-inositol in the carob extract is ≥80%.
3. The composition according to claim 2, characterized in that The zinc-containing compound includes at least one of zinc sulfate, zinc citrate, zinc gluconate, zinc oxide, zinc lactate, zinc acetate and zinc chloride.
4. The composition according to claim 3, characterized in that In the composition: The mass ratio of flaxseed concentrated powder: carob extract: red ginseng: zinc-containing compound is (2-15): (0.5-12): (0.7-15): (0.01-0.1).
5. The composition according to claim 1, characterized in that The composition further comprises: vitamins; and / or One or more pharmaceutically acceptable excipients.
6. Use of the composition according to any one of claims 1 to 5 in the preparation of a medicament for delaying ovarian aging and improving polycystic ovary syndrome.
7. The use according to claim 6, characterized in that The dosage forms of the drug include tablets, liquid preparations, capsules and powders.
